Table 3. Treatment of gastric cancer with ZD6126: time course.

		ZD6126 (100 mg kg−1)
	Control	Day 1	Day 3	Day 5
Tumour weight (g)	0.6±0.3	0.3±0.06	0.2±0.01	0.3±0.02
Tumour volume (mm3)	250.1±75.7	242.6±31.0	167.8±47.3	134.2±34.6
Proliferating cells # of cells/HPF	112.3±7.3	43.7±14.7a	78.4±14.6b	33.0±10.0a
Apoptotic cells # of cells/HPF	0.8±0.3	12.0±6.6b	16.2±7.9c	7.2±3.3b
Microvessel density # of vessels/HPF	32.9±2.7	29.3±2.4	25.7±2.9	22.8±2.6a
Proliferating EC # of cells/HPF	2.5±0.4	1.1±0.3b	1.1±0.18c	1.3±0.3b
Apoptotic EC # of cells/HPF	0.6±0.1	0.7±0.3	1.2±0.3	0.6±0.1
Ratio of apoptotic to proliferating ECs (% control)	0.3	0.6c (57%)	1.1c (67%)	0.8b (68%)

TMK-1 tumours growing in the gastric wall were harvested at 1 day, 3 days and 5 days post-ZD6126 injection. Tissue sections were stained with antibodies against CD31, BrdU and TUNEL to determine MVD, endothelial cell proliferation and endothelial cell apoptosis. Measurements are the mean±the standard error, as determined by counting the positive cells in each of five × 100 high-powered fields (HPF) for three tumours from each treatment or control group. EC=endothelial cell.

^aP<0.004.

^bP<0.05.

^cP<0.01.